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Abstract: 
A scFv (single chain variable fragment) antibody clone from anti-CMV (anti-cucumber mosaic virus) was successfully 
constructed from immunized mouse and the DNA sequence was submitted to GenBank (AY337618 and AY337619). The 
expression of a 32 kDa recombinant antibody in bacteria was verified using ELISA (enzyme-linked immunoassay) and western 
blot. However, elucidation of specific anti-CMV scFv function requires detailed and time consuming immuno-assays. 
Alternatively, useful functional information on anti-CMV scFV antibody can be obtained using available Bioinformatics tools 
and techniques without performing tedious assays. Here, we use the commonly used Bioinformatics tools and databases such as 
BLAST (basic local alignment search tool), GenBank, PDB (protein databank), KABAT numbering, SWISS-MODEL and 
Insight II to gain specific functional insights into anti-CMV scFv. 
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Background: 
Functional antibodies have been extensively used in 
pharmaceutical and clinical applications. Antibodies have a 
typical structure consisting of two identical heavy and light 
chains joined together by disulfide and non-covalent bonds. 
Fv (variable fragment) plays a role in the antigen-binding 
activities of an immunoglobulin molecule. It is the smallest 
unit of immunoglobulin and is easily manipulated for 
immunological application. [1,  2,  3] ScFv (single-chain 
variable fragment) refers to the antibody fragments consisting 
of VH (heavy) and VL (light) chains connected by a peptide 
linker. [4, 5, 6]  
 
ScFvs are commonly constructed from hybridoma, mouse 
immunoglobulin, sheep immunoglobulin [ 7], chicken 
immunoglobulin [8, 9] and human antibody repertoire. [10, 
11] They are generally produced at large scales using 
genetically engineered cloning vectors in bacterial hosts. [12] 
The most widely used peptide linker in scFv construction 
consists of a 15 residues sequence with repeats (Gly4Ser)3. 
The linker provides the molecule with a flexibility to move 
approximately 35 to 40 Å between the carboxy terminal of the 
VH and the amino terminus of the VL chains. [5, 6] It should 
be noted that the affinity and stability of the scFv antibodies 
containing the (Gly4Ser)3 residues are generally comparable 
to those of the native antibody. [6] However, in some other 
antibody classes, the linker is made of residues GLU and LYS 
and they have a role in the solubility enhancement of scFv. 
[13] The stability and affinity is mainly contributed by 
disulfide bond linkers in these molecules. [14,  15] Despite 
availability of several scFv structures at the PDB, the anti-
CMV scFv structure is not known. In this report, we describe 
sequencing, GenBank data submission, modelling of an anti-





Plasmid Extraction and sequencing  
Plasmid DNA of the anti-CMV ScFv antibody clone was 
prepared from bacterial culture using QIAGEN plasmid mini 
kit and subjected to sequencing using an ABI 3770 automated 
sequencer. The obtained sequences were then submitted to 
GenBank (AY337618 and AY337619). 
 
Anti-CMV ScFv antibody sequence 
The nucleotide sequences were then translated into protein 
sequences using the TRANSLATE program at Expasy. [24]  
 
Sequence database search 
Sequence database search for VH (variable heavy chain) and 
VL (variable light chain) was performed using the BLAST 
program at NCBI. [16, 25]  
 
Expression analysis 
The expression of a 32 kDa recombinant antibody in bacteria 
was verified using ELISA (enzyme-linked immunoassay) and 
western blot. 
 
CDR (complementarity determining regions) 
The CDR regions in the anti-CMV ScFv were determined 
using KABAT numbering [26] and their canonical structures 
were determined using Chothia description. [17, 22]  
 
Homology modeling and energy minimization 
SWISS-MODEL was used to model VH and VL chains 
separately. [18, 19, 20, 26] The VH and VL models were then 
connected by a synthetic peptide [(Gly4Ser)3] using 
BUILDER/Insight II [27] followed by energy minimization in  
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Results and Discussion: 
A phage display technology was successfully carried out to 
develop an anti-CMV scFv recombinant antibody as an 
alternative to the tedious and time-consuming hybridoma 
development. The approximately 700 bp scFv gene was 
successfully constructed and expressed in bacteria. [21] We then 
sequenced the anti-CMV scFv gene and deposited the sequence 
at GenBank (AY337618 and AY337619). A number of scFv 
structures at PDB (www.rcsb.org/pdb) and general information 
on antigen binding are well document. However, different scFv 
molecules from varying sources have different antigen binding 
functional properties in quantitative measures. Therefore, it is 
our particular interest to probe specifically into the structure of 
an anti-CMV scFv antibody, whose structure is not known. The 
GenBank submitted VH and VL chains of an anti-CMV scFv 
antibody with translated protein sequence are shown in Figure 1. 
A total of six CDRs (three in each chain) are identified using 
KABAT numbering and are highlighted in BOLD (Figure 1).  
 
 
Figure 1: DNA and protein sequences for VH and VL chains. 
The GenBank deposited nucleotide sequences for VH (GenBank 
Accession Number AY337618) and VL (GenBank Accession 
Number AY337619) chains were obtained from in-house 
sequencing and the TRANSLATE program is used to translate 
into protein sequences. The 3 CDRs for both the chains were 
obtained using KABAT numbering and the CDR sequences are 
shown in boldface 
 
 
Figure 2: BLASTP search hit for anti-CMV ScFv against 
PDB (protein databank). The results show that the anti-CMV 




Figure 3: Canonical structures for CDRs in anti-CMV ScFv 
antibody. (A) Heavy chain: CDR-H1 (red), CDR-H2 (yellow) 
and CDR-H3 (green). (B)  Light chain: CDR-L1 (purple), 
CDR-L2 (orange) and CDR-L3 (blue) 
 
 
Figure 4: The anti-CMV ScFv antibody model shown in CPK 
display: The CPK model show all the CDRs on the surface of 
the molecule. The peptide linker (Turquoise), CDR-H1 (red), 
CDR-H2 (yellow) and CDR-H3 (green), CDR-L1 (magenta), 
CDR-L2 (orange) and CDR-L3 (blue). This model was built 
by joining VH and VL chains together by a peptide using 
BUILDER/Insight II and energy minimized in CFF91 force 
field 
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The distribution of CDRs in different regions of the VH and VL 
sequences is insightful, yet limited due to lack of 3D 
information. Hence, we searched the anti-CMV scFv protein 
sequence against PDB (protein database) using BLASTP to 
identify suitable templates for homology modelling (Figure 2). 
PDB search results show a high sequence similarity (82%) a 
synthetic peptide. Thus, the availability of a structural homolog 
at PDB was confirmed. We then submitted the anti-CMV scFv 
antibody sequence to SWISS-MODEL and the VH and VL 
structures were separately modelled. The models are represented 
in ribbons generated using RasMol [29] in Figure 3. The 
canonical conformations for CDRs in anti-CMV scFv are 
mapped in 3D and mapped regions are shown in Figure 3. The 
individually modelled VH and VL  structures were linked by a 
synthetic peptide [(Gly4Ser)3] using BUILDER/Insight II [27] 
followed by energy minimization in  CFF91 force field. The 
modeled anti-CMV scFv structure is represented in CPK model 
and CDRs mapped. Thus, the structure of an anti-CMV scFv 
was modeled and CDRs mapped to the structure in 3D. 
However, the regions of CDR involved in antigen-binding are 
not known for anti-CMV scFv. Therefore, further studies are 
required to identify the antigen binding CDRs.  
 
Conclusion:  
The anti-CMV scFv antibody gene was sequenced and the 
sequence submitted to GenBank. To gain functional insight, the 
scFv antibody structure was modelled using SWISS-MODEL 
and Insight II. The CDRs in the modelled antibody structure 
were determined by KABAT numbering and mapped to provide 
insight for further epitope analysis. Thus, the identification and 
elucidation of CDRs in the anti-CMV scFv antibody is 
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